The cancer immunotherapy ‘Opdivo’ is attempting to add another esophageal cancer indication as a combination therapy in Korea.

According to industry sources, the Ministry of Food and Drug Safety is reviewing expanding the indication for Ono·BMS’s PD-1 inhibitor Opdivo (nivolumab) in combination with Yervoy (ipilimumab) or chemotherapy as first-line treatment for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

The combinations are under review by the EU EMA for the same esophageal cancer indication.

The efficacy of the Opdivo-based combination therapy as first-line treatment in esophageal cancer was demonstrated through the Phase III C